Showing results (811-820 of 881) with videos related to

Sort By:
Pageof 89
Lancet (London, England)|December 4, 2014
Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trialMark Sulkowski, Christophe Hezode, Jan Gerstoft, et al.
Hepatology (Baltimore, Md.)|October 15, 2014
Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virusEric M Yoshida, Mark S Sulkowski, Edward J Gane, et al.
Gut|August 30, 2011
Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3Alexander J Thompson, Keyur Patel, Wan-Long Chuang, et al.
The New England Journal of Medicine|April 12, 2014
Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirinStefan Zeuzem, Ira M Jacobson, Tolga Baykal, et al.
Gastroenterology|May 26, 2012
Factors that predict response of patients with hepatitis C virus infection to boceprevirFred Poordad, Jean-Pierre Bronowicki, Stuart C Gordon, et al.
Alimentary Pharmacology & Therapeutics|October 30, 2016
All-oral direct-acting antiviral therapy in HCV-advanced liver disease is effective in real-world practice: observations through HCV-TARGET databaseK R Reddy, J K Lim, A Kuo, et al.
Gastroenterology|August 12, 2019
Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir TherapyAnna S Lok, Mark S Sulkowski, Jens J Kort, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 23, 2018
Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 StudyJürgen K Rockstroh, Karine Lacombe, Rolando M Viani, et al.
Hepatology International|February 18, 2017
Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label studyMark S Sulkowski, Walford J Fessel, Adriano Lazzarin, et al.
Hepatology (Baltimore, Md.)|April 8, 2015
Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysisK Rajender Reddy, Marc Bourlière, Mark Sulkowski, et al.
Pageof 89